European Cell Therapy Players TiGenix And Cellerix Join Forces For Critical Mass, Cash
This article was originally published in The Pink Sheet Daily
Lacking critical mass individually, Belgium's TiGenix and Spain's Cellerix have joined forces, attracting €33 million in new investment.
You may also be interested in...
At a 9% premium to Eurand's closing stock price Nov. 30, the value is disappointing, but majority investor Warburg Pincus favors the deal and competitive bids are unlikely.
Signs are that Spanish biotech, until now held back by a lack of capital and management expertise, may be about to receive the kick-start it badly needs. Newly-created Ysios Capital Partners is the country's first specialist VC. It's raising a first fund worth €65 million ($92 million)--and it's not alone.
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.